Regulatory Milestones and Campaigns in the Presbyopia Market During Q4 2025 Q4 2025 gMG Market Driven by Clinical Progress and Regulatory Milestones

Phentolamine (MR-141) messaging highlighted the planned year-end 2025 supplemental NDA submission for Phentolamine Ophthalmic Solution 0.75% for presbyopia, supported by a strengthened capital position to advance regulatory and development efforts.

Following FDA approval, Qlosi materials emphasized strong commercial uptake and access-driven programs, including Starter Packs and the “Your Clear Start Week” onboarding initiative, while reinforcing key clinical attributes through expert-led education.

Vizz capitalized on its FDA approval through the “Eye Am” and “Make it VIZZable” campaigns, promoting once-daily efficacy up to 10 hours, ECP and patient testimonials, and broad commercialization efforts targeting 128 million U.S. presbyopes, alongside international regulatory progress with an MFDS submission in South Korea.